Use of PEGylated Immunoliposomes to Deliver Dopamine Across the Blood–Brain Barrier in a Rat Model of Parkinson's Disease
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: Aim: To treat neurodegenerative disorders such as Parkinson's disease (PD), drugs must be able to cross the blood–brain barrier (BBB). Patients with PD are deficient in dopamine (DA), a neurotransmitter that cannot pass through the BBB. Liposomes modified by adding polyethylene glycol (PEG ylated liposomes (PL s)) can be conjugated with antibody to form DA–PEG ylated immunoliposomes (DA‐PIL s), and we tested their use as carriers of DA for treating PD. Methods: PEG ylated liposomes (PL s) were prepared by evaporation method, and [3 H]dopamine was encapsulated within the dried lipid film using a freeze/thaw cycle to form DA‐PL. Thiolated OX 26 MA b, an antitransferrin receptor monoclonal antibody, was then conjugated to 46‐nm PEG ylated liposomes. Particle size, zeta potential, and stability were assessed, and in vivo effects were determined after the intravenous injection of DA, DA‐PL, and DA‐PIL by examining brain tissue in normal rats and rats that underwent transection of the medial forebrain bundle to induce PD. Results: The uptake of DA‐PIL in the brains of this PD rat model increased about 8‐fold compared with that of DA alone and about 3‐fold compared with that of encapsulated DA–PEG ylated liposomes (DA‐PL). The volume of distribution of DA‐PIL in the brain by the perfusion method was 4‐fold higher than that of DA‐PL, indicating that conjugation of OX 26 MA b to the transferrin receptor of brain capillary endothelium mediated the effective delivery of DA to brain tissue. Conclusions: Dopamine can be effectively delivered to the brain by means of a PIL‐based drug delivery system in PD rats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The genetic epidemiology of neurodegenerative disease
Bertram, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24761 · Cited by 680 · cited 1×
“Every year, more than 10 million people globally are diagnosed with neurodegenerative diseases such as Alzheimer’s disease or PD [2].”
BackgroundThe blood-brain barrier: structure, function and therapeutic approaches to cross it.
Tajes, M., Ramos-Fernández, E., Weng-Jiang, X., Bosch-Morató, M., Guivernau, B., Eraso-Pichot, A., Salvador, B., Fernàndez-Busquets, X., Roquer, J., & Muñoz, F. J. (2014) · Molecular Membrane Biology · doi:10.3109/09687688.2014.937468 · Cited by 380
Cited by
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
“[86] encapsulated dopamine into PEGylated liposomes that was then conjugated to the anti-transferrin receptor monoclonal antibody, OX26.”
MethodTargeting the transferrin receptor for brain drug delivery
Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 370
Teixeira, M. I., Lopes, C. M., Amaral, M. H., & Costa, P. C. (2023) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2022.112999 · Cited by 154
Kim, M., Shin, M., Zhao, Y., Ghosh, M., & Son, Y. (2024) · Small Science · doi:10.1002/smsc.202400280 · Cited by 97
Pramoda, G., Verma, R. K., Kesharwani, P., & Shukla, R. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.127938 · Cited by 15
Metadata
- Authors
- Kang, Y., Jung, H., Oh, J., & Song, D.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2016-06-27
- Volume
- 22
- Issue
- 10
- Pages
- 817-823
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W2471002179
- Cited by
- 68
- References
- 2
- FWCI
- 1.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.